Clinical trial · Interventional
Intraperitoneal Irrigation of Ondansteron in Combination With Lidocaine in Acute Postoperative Pain
Impact of Intraperitoneal Irrigation of Ondansteron in Combination With Lidocaine in Acute Postoperative Pain in Lower Abdominal Cancer Surgery: a Randomized Clinical Trial
NCT07706348CI-TRIAL-00118106recruitingPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study, therefore, aimed to investigate the effect of intraperitoneal administration of ondansetron in combination to lidocaine for postoperative pain management in patients undergoing lower abdominal cancer surgery.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acue Postoperative Pain | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ondansteron | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Ondansetron group (O group)
- description
- 8 mg ondansetron (4 mL) IP with 2% lidocain in dose 4mg/kg in total volume 30 ml instillation at the end of the procedure
- interventionNames
- Drug: ondansteron
- type
- PLACEBO_COMPARATOR
- label
- control group (C group)
- description
- lidocaune in dose 4mg/kg in total volume 30 ml with normal saline IP with lidocaine at the end of the procedure
- interventionNames
- Drug: ondansteron
Primary outcomes (1)
- measure
- total morphine consumption
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * ASA I-II patients * scheduled for major lower abdominal cancer surgeries. Exclusion Criteria: * patients with known allergy to the study drugs, * significant cardiac, respiratory, renal or hepatic disease, * body mass index (BMI) ≥30 kg/m2; * allergy to study drugs * history of opioid use for pain management the time of enrolment or drug addiction, * who had used benzodiazepine chronically, * stroke or psychiatric disease that could affect the perception of pain.
References
Publications (0)
Data not yet available
No reference posted for this study.